Exporting Homeopathic Products to the United States: FDA Registration and Compliance Requirements

Homeopathic products are classified as drugs under the Federal Food, Drug, and Cosmetic Act — not as dietary supplements, not as cosmetics, and not as a separate regulatory category. This classification means that foreign manufacturers of homeopathic products must comply with the same FDA registration and listing requirements that apply to conventional pharmaceutical manufacturers: drug establishment registration under 21 CFR Part 207, NDC Labeler Code acquisition, drug product listing, and compliance with applicable manufacturing and labeling standards. Many foreign homeopathic manufacturers — particularly those from Germany, France, India, and other countries with strong homeopathic traditions — are surprised to learn that the US regulatory framework treats their products the same as conventional OTC drugs in terms of registration obligations.

The Homeopathic Pharmacopoeia of the United States

The legal basis for homeopathic drug regulation in the United States is the recognition of the Homeopathic Pharmacopoeia of the United States (HPUS) in Section 201(g)(1) of the FD&C Act, which defines a drug as, among other things, an article recognized in the official Homeopathic Pharmacopoeia. For a homeopathic product to be marketed as a drug in the US, its active ingredients must be listed in the HPUS or must meet the criteria for inclusion. Products that contain ingredients not recognized in the HPUS may be considered unapproved new drugs, which would require an NDA or ANDA before marketing. The HPUS is maintained by the Homeopathic Pharmacopoeia Convention of the United States (HPCUS) and is updated periodically to include new monographs.

FDA registration and listing for homeopathic manufacturers

Foreign establishments that manufacture, process, or pack homeopathic drug products for the US market must register with the FDA annually under 21 CFR Part 207 and designate a US Agent. The company must obtain an NDC Labeler Code and list each homeopathic product through FDA's eDRLS system using SPL format. The listing must include the product's ingredients (identified by their HPUS names), potency (dilution), dosage form, route of administration, and labeling. Annual establishment fees apply under GDUFA, the same as for conventional drug establishments. Foreign homeopathic manufacturers are subject to the same fee structure as conventional pharmaceutical manufacturers.

Manufacturing standards for homeopathic drugs

Homeopathic drug products must be manufactured in compliance with CGMP requirements under 21 CFR Parts 210 and 211, with modifications appropriate to the nature of homeopathic manufacturing processes. The HPUS provides manufacturing guidelines specific to homeopathic preparations, including dilution procedures, trituration methods, and potentization (succussion) protocols. The FDA has historically applied CPG 400.400 (Conditions Under Which Homeopathic Drugs May Be Marketed) to define the compliance framework for homeopathic products, although the agency has signaled that this guidance may be revised. Homeopathic manufacturers must maintain the same quality control documentation, batch records, and testing protocols as conventional drug manufacturers, adapted to the specific characteristics of homeopathic production processes.

Labeling requirements for homeopathic drugs

Homeopathic drug labeling must comply with the Drug Facts format under 21 CFR 201.66 for OTC products. The label must include the active ingredients identified by their HPUS names, the potency expressed in standard homeopathic notation (such as 6X, 30C, or 200CK), the purpose of each active ingredient, the product's uses (indications), warnings, directions for use, and inactive ingredients. The indications must be limited to conditions that are self-diagnosable and self-treatable — conditions appropriate for OTC self-medication. Claims to treat serious medical conditions that require professional diagnosis or treatment are not appropriate for OTC homeopathic labeling and may result in FDA enforcement action.

FDA enforcement trends for homeopathic products

The FDA has increased its enforcement scrutiny of homeopathic products in recent years, particularly products marketed for serious conditions (such as cancer, heart disease, or opioid addiction), products that pose safety risks due to their formulation or route of administration, and products marketed for use in children. The FDA has issued Warning Letters to companies making unsubstantiated therapeutic claims for homeopathic products and has taken enforcement action against products containing potentially toxic ingredients at insufficiently diluted levels. The 2017 FDA draft guidance on homeopathic drug products proposed a risk-based enforcement framework that would prioritize products with the highest potential for harm, but as of 2026, the final guidance has not been issued.

How FDABridge handles homeopathic drug registration

FDABridge provides drug establishment registration, NDC Labeler Code acquisition, and drug product listing services for foreign homeopathic manufacturers. We handle the SPL formatting and electronic submission requirements and ensure your homeopathic product listings accurately reflect HPUS nomenclature and labeling requirements. Visit fdabridge.com/drug to see our drug registration services or fdabridge.com/contact to discuss your homeopathic product compliance.